© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
cells from prostate cancer patients with short telomeres and hypervariable lengths were 14X more likely to die of their disease
- Written:
- Author: Edward
- Posted in: cancer, dr ed park, Podcasts, stem cell theory of aging
- Tags: cancer, Dr. Ed Park, hypervariability, meeker, mortality, prostate cancer
Reading Time: < 1 minute
Live Webinar WED at 2PM PST- Prostate Cancer
Please join us tomorrow for a live webinar on prostate cancer. If you can’t make it, we will be posting the edited final broadcast to YouTube
PODCAST 47: Prostate Cancer
Wed, Jul 1, 2015 2:00 PM – 2:45 PM PDT
Please join my meeting from your computer, tablet or smartphone.
https://global.gotomeeting.com/join/903356061
You can also dial in using your phone.
United States : +1 (646) 749-3122
Access Code: 903-356-061
In this study by Meeker et al from Johns Hopkins, they found that cells from prostate cancer patients with short telomeres and hypervariable lengths were 14X more likely to die of their disease; 20 out 80 died of their disease and average of 8.4 years later.
In contrast, in those with less variability only 1 out of 98 died 16.5 years after diagnosis.
These findings are in keeping with my Stem Cell Theory of Aging and Disease and the notion that high telomerase activity is consistent with both prevention of the inciting mutation events and better apoptosis and clearing of damaged stem cells that have hypervariable lengths from mutation and continued telomerase activity due to failed apoptosis.
